IXICO (LON:IXI) advanced in early deals after revealing a strategic collaboration with an un-named leading pharmaceutical company and independent expert clinical centres.
The collaboration is expected to see IXICO develop an adapted version of its digital healthcare platform to help monitor and manage approved pharmaceutical treatments for multiple sclerosis in the EU and Canada.
It is expected to start this month, and the anticipated table sees the platform in a clinical setting in 2016.
Chief executive Professor Derek Hill expects the collaboration to make a material contribution to IXICO’s revenue in the next 12-18 months, which he says underpins the group’s confidence in meeting market expectations.
John Hall, IXICO senior vice president of commercial operations, meanwhile, said: “We are delighted that this new collaboration will expand the use of our Assessa platform into another clinical area alongside currently approved treatments, further extending the reach and application of our technology and expertise.”
In early deals, IXICO shares gained up to 8% to trade at 33p each.